{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:08:59Z","timestamp":1777349339582,"version":"3.51.4"},"reference-count":92,"publisher":"Georg Thieme Verlag KG","funder":[{"name":"Swedish Cancer Society","award":["22 2109Fk"],"award-info":[{"award-number":["22 2109Fk"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Coagulopathies are common in hematological malignancies and can cause life-threatening bleeding or thrombosis. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, carry cargo that reflects their cellular origin. They frequently express tissue factor (TF) and expose phosphatidylserine (PS), which initiate and amplify coagulation and can also transport fibrinolytic mediators that modulate plasmin generation. Procoagulant EVs are commonly assessed using TF- and PS-dependent functional assays, global hemostasis tests such as overall hemostatic potential, and flow cytometric phenotyping. Clinical and experimental data show elevated EV numbers and activity at diagnosis in several hematological malignancies. In acute leukemias, EV-associated procoagulant activity often declines with treatment yet may remain above control levels, consistent with residual risk. In plasma cell disorders and myeloproliferative neoplasms, platelet-derived and TF\/PS-positive EVs are frequently increased and have been linked to enhanced thrombin generation. EVs appear to play key roles across leukemias, multiple myeloma, lymphoid, and myeloproliferative neoplasms. However, considerable methodological heterogeneity, including differences in preanalytical handling, EV isolation, characterization, and activity measurement, limits comparability and clinical translation. Disease-specific mechanistic studies are needed to clarify how EVs modulate hemostasis in different hematologic malignancies. In parallel, standardized protocols and adequately powered clinical studies are required to validate EVs as biomarkers.<\/jats:p>","DOI":"10.1055\/a-2799-0557","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:15:44Z","timestamp":1770941744000},"source":"Crossref","is-referenced-by-count":1,"title":["Extracellular Vesicles Drive Coagulopathy Across Hematologic Cancers"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6069-6615","authenticated-orcid":false,"given":"Charlotte","family":"Gran","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet, Stockholm, Sweden"},{"name":"Clinical Chemistry, Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna","family":"Nor\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medicine Huddinge, Gastroenterology and Rheumatology Unit, Karolinska Institute, Stockholm, Sweden"},{"name":"Department of Hepatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan P.","family":"Antovic","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet, Stockholm, Sweden"},{"name":"Clinical Chemistry, Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"29","key":"ref1","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"A Falanga","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"ref2","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"M Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"A Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"R F Grace","year":"2011","journal-title":"Br J Haematol"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"M A Sanz","year":"2009","journal-title":"Blood"},{"issue":"13","key":"ref6","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.3390\/cancers15133477","article-title":"The coagulopathy of acute promyelocytic leukemia: an updated review of pathophysiology, risk stratification, and clinical management","volume":"15","author":"J Hermsen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"13","key":"ref7","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"T Barbui","year":"2013","journal-title":"Blood"},{"issue":"S 01","key":"ref8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10428199609074364","article-title":"Acquired von Willebrand disease in myeloproliferative disorders","volume":"22","author":"P J van Genderen","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"07","key":"ref9","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/cancers12071746","article-title":"Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding","volume":"12","author":"H Awada","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3402\/jev.v3.24400","article-title":"Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer","volume":"3","author":"C Bouvy","year":"2014","journal-title":"J Extracell Vesicles"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.3390\/cancers13153839","article-title":"Tissue factor and extracellular vesicles: activation of coagulation and impact on survival in cancer","volume":"13","author":"Y Hisada","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/diagnostics10121065","article-title":"Extracellular vesicles in hematological malignancies: from biomarkers to therapeutic tools","volume":"10","author":"J Khalife","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"G Raposo","year":"2013","journal-title":"J Cell Biol"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/pr.112.005983","article-title":"Classification, functions, and clinical relevance of extracellular vesicles","volume":"64","author":"E van der Pol","year":"2012","journal-title":"Pharmacol Rev"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/ijms18061183","article-title":"Extracellular vesicles in hematological malignancies: from biology to therapy","volume":"18","author":"A Caivano","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2017.11.014","article-title":"Microparticles in hematological malignancies: role in coagulopathy and tumor pathogenesis","volume":"355","author":"S Ball","year":"2018","journal-title":"Am J Med Sci"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"e0227932","DOI":"10.1371\/journal.pone.0227932","article-title":"Use of thrombodynamics for revealing the participation of platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation","volume":"15","author":"E N Lipets","year":"2020","journal-title":"PLoS One"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/cells10092316","article-title":"The power of extracellular vesicles in myeloproliferative neoplasms: \u201ccrafting\u201d a microenvironment that matters","volume":"10","author":"L Catani","year":"2021","journal-title":"Cells"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1160\/TH06-06-0313","article-title":"Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets","volume":"97","author":"E I Sinauridze","year":"2007","journal-title":"Thromb Haemost"},{"issue":"15","key":"ref20","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.3390\/ijms23158827","article-title":"Extracellular vesicles in myeloid neoplasms","volume":"23","author":"C Karantanou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"13","key":"ref21","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/CIRCULATIONAHA.112.094920","article-title":"Deletion of microvesicles from the circulation","volume":"125","author":"P E Rautou","year":"2012","journal-title":"Circulation"},{"issue":"08","key":"ref22","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1538-7836.2009.03504.x","article-title":"Microparticle-associated tissue factor activity in cancer patients with and without thrombosis","volume":"7","author":"M E Tesselaar","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCRESAHA.110.233056","article-title":"Microparticles in hemostasis and thrombosis","volume":"108","author":"A P Owens III","year":"2011","journal-title":"Circ Res"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/rth2.12165","article-title":"Measurement of tissue factor activity in extracellular vesicles from human plasma samples","volume":"3","author":"Y Hisada","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3390\/cancers15071957","article-title":"Microparticle phosphatidylserine mediates coagulation: involvement in tumor progression and metastasis","volume":"15","author":"H Jing","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3324\/haematol.2012.066167","article-title":"Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis","volume":"97","author":"R Lacroix","year":"2012","journal-title":"Haematologica"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"1688936","DOI":"10.1080\/20013078.2019.1688936","article-title":"Extracellular vesicles and coagulation in blood from healthy humans revisited","volume":"8","author":"R J Berckmans","year":"2019","journal-title":"J Extracell Vesicles"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"e70073","DOI":"10.1002\/jev2.70073","article-title":"The procoagulant and fibrinolytic balance of extracellular vesicles predicts mortality in septic shock patients","volume":"14","author":"R Lacroix","year":"2025","journal-title":"J Extracell Vesicles"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3402\/jev.v2i0.20360","article-title":"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research","volume":"2","author":"K W Witwer","year":"2013","journal-title":"J Extracell Vesicles"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/CIRCRESAHA.117.309417","article-title":"Methodological guidelines to study extracellular vesicles","volume":"120","author":"F AW Coumans","year":"2017","journal-title":"Circ Res"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"e12400","DOI":"10.1002\/jev2.12400","article-title":"A beginner's guide to study extracellular vesicles in human blood plasma and serum","volume":"13","author":"R Nieuwland","year":"2024","journal-title":"J Extracell Vesicles"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1194\/jlr.R084640","article-title":"Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA","volume":"59","author":"E Boilard","year":"2018","journal-title":"J Lipid Res"},{"issue":"01","key":"ref33","first-page":"80","article-title":"Isolation and analysis methods of extracellular vesicles (EVs)","volume":"2","author":"Z Zhao","year":"2021","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"issue":"17","key":"ref34","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.3390\/ijms21176257","article-title":"Measuring extracellular vesicles by conventional flow cytometry: dream or reality?","volume":"21","author":"D Lucchetti","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"1713526","DOI":"10.1080\/20013078.2020.1713526","article-title":"MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments","volume":"9","author":"J A Welsh","year":"2020","journal-title":"J Extracell Vesicles"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jth.15540","article-title":"Minimum information to report about a flow cytometry experiment on extracellular vesicles: communication from the ISTH SSC subcommittee on vascular biology","volume":"20","author":"E van der Pol","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"1454777","DOI":"10.1080\/20013078.2018.1454777","article-title":"Investigation of procoagulant activity in extracellular vesicles isolated by differential ultracentrifugation","volume":"7","author":"T Nielsen","year":"2018","journal-title":"J Extracell Vesicles"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.13106","article-title":"Circulating tissue factor-positive extracellular vesicles and their association with thrombosis in different diseases","volume":"312","author":"Y Hisada","year":"2022","journal-title":"Immunol Rev"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jtha.2024.05.037","article-title":"Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology","volume":"22","author":"A Bonifay","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1055\/s-0040-1710032","article-title":"Synergistic effect of bypassing agents and sequence identical analogue of emicizumab and fibrin clot structure in the in vitro model of hemophilia A","volume":"4","author":"Y Zong","year":"2020","journal-title":"TH Open"},{"issue":"17","key":"ref41","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival","volume":"113","author":"G H Ku","year":"2009","journal-title":"Blood"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1538-7836.2005.01467.x","article-title":"The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment","volume":"3","author":"V De Stefano","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"107694","DOI":"10.1016\/j.leukres.2025.107694","article-title":"Incidence and risk factors of venous thromboembolism in patients with acute Leukemia: a systematic review and meta-analysis","volume":"153","author":"W Zhang","year":"2025","journal-title":"Leuk Res"},{"issue":"11","key":"ref44","first-page":"1530","article-title":"The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia","volume":"91","author":"K Webert","year":"2006","journal-title":"Haematologica"},{"issue":"S 02","key":"ref45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428199309064261","article-title":"Bleeding and thrombosis in acute lymphoblastic leukemia","volume":"11","author":"T Barbui","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0609.2006.00803.x","article-title":"Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome","volume":"78","author":"M Yanada","year":"2007","journal-title":"Eur J Haematol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fonc.2020.00090","article-title":"Extracellular vesicles and chemotherapy resistance in the AML microenvironment","volume":"10","author":"J Nehrbas","year":"2020","journal-title":"Front Oncol"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","article-title":"Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer","volume":"13","author":"A A Khorana","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.thromres.2012.09.020","article-title":"Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients","volume":"131","author":"J Thaler","year":"2013","journal-title":"Thromb Res"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.beha.2014.04.005","article-title":"The coagulopathy in acute promyelocytic leukaemia\u2013what have we learned in the past twenty years","volume":"27","author":"H C Kwaan","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-2007-976168","article-title":"The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia","volume":"33","author":"M S Tallman","year":"2007","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jtha.2024.03.020","article-title":"Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia","volume":"22","author":"Y Hisada","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00277-021-04533-9","article-title":"Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study","volume":"100","author":"H Zhao","year":"2021","journal-title":"Ann Hematol"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00277-013-1676-6","article-title":"Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia","volume":"92","author":"G Ma","year":"2013","journal-title":"Ann Hematol"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jth.13236","article-title":"Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study","volume":"14","author":"R Tuckuviene","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.exphem.2015.07.004","article-title":"Disease dynamics in patients with acute myeloid leukemia: new biomarkers","volume":"43","author":"I Tzoran","year":"2015","journal-title":"Exp Hematol"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1538-7836.2010.04133.x","article-title":"Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy","volume":"9","author":"M C Van Aalderen","year":"2011","journal-title":"J Thromb Haemost"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40164-015-0018-x","article-title":"Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study","volume":"4","author":"C Dicke","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.thromres.2013.12.029","article-title":"Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia","volume":"133","author":"J Thaler","year":"2014","journal-title":"Thromb Res"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11239-016-1471-z","article-title":"Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia","volume":"43","author":"D Gheldof","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"ref61","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/jth.13871","article-title":"Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer","volume":"15","author":"K Date","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11239-020-02346-7","article-title":"A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?","volume":"51","author":"C Pluchart","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"26","key":"ref63","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","article-title":"Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events","volume":"115","author":"V Caruso","year":"2010","journal-title":"Blood"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/cancers12051291","article-title":"Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis","volume":"12","author":"S Hohaus","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"1995166","DOI":"10.1080\/2162402X.2021.1995166","article-title":"Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma","volume":"10","author":"J W Li","year":"2021","journal-title":"OncoImmunology"},{"issue":"21","key":"ref66","doi-asserted-by":"crossref","first-page":"13327","DOI":"10.3390\/ijms232113327","article-title":"Extracellular vesicles in diffuse large B cell lymphoma: characterization and diagnostic potential","volume":"23","author":"R Matthiesen","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"17","key":"ref67","doi-asserted-by":"crossref","first-page":"10118","DOI":"10.3390\/ijms231710118","article-title":"Extracellular vesicles in haematological disorders: a friend or a foe?","volume":"23","author":"I Lazana","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"ref68","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.3390\/ijms26125655","article-title":"Extracellular vesicles profile and risk of venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"26","author":"V Otasevic","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/cam4.2134","article-title":"Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors","volume":"8","author":"P Georgantopoulos","year":"2019","journal-title":"Cancer Med"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"P M Barr","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"A H Lipsky","year":"2015","journal-title":"Haematologica"},{"issue":"20","key":"ref72","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","article-title":"A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"L S Quek","year":"1998","journal-title":"Curr Biol"},{"issue":"08","key":"ref73","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2006-01-011817","article-title":"Bruton tyrosine kinase is essential for botrocetin\/VWF-induced signaling and GPIb-dependent thrombus formation in vivo","volume":"108","author":"J Liu","year":"2006","journal-title":"Blood"},{"issue":"02","key":"ref74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"C Eby","year":"2009","journal-title":"Br J Haematol"},{"issue":"S 01","key":"ref75","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0049-3848(12)70024-5","article-title":"Risk and management of thrombosis in multiple myeloma","volume":"129","author":"F W Leebeek","year":"2012","journal-title":"Thromb Res"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"R A Kyle","year":"2008","journal-title":"Blood"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"M Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JBM.S147743","article-title":"Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma","volume":"9","author":"S Nomura","year":"2018","journal-title":"J Blood Med"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"e0210835","DOI":"10.1371\/journal.pone.0210835","article-title":"Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma","volume":"14","author":"T Nielsen","year":"2019","journal-title":"PLoS One"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.thromres.2021.03.015","article-title":"Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"202","author":"T Nielsen","year":"2021","journal-title":"Thromb Res"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1160\/TH10-03-0187","article-title":"Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma","volume":"105","author":"J J Auwerda","year":"2011","journal-title":"Thromb Haemost"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"109256","DOI":"10.1016\/j.thromres.2025.109256","article-title":"Tissue factor-bearing extracellular vesicles, procoagulant phospholipids and D-dimer as potential biomarkers for venous thromboembolism in patients with newly diagnosed multiple myeloma: a comprehensive analysis","volume":"247","author":"S Charles","year":"2025","journal-title":"Thromb Res"},{"issue":"08","key":"ref83","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study","volume":"17","author":"K Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref84","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"A Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref85","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3324\/haematol.13774","article-title":"Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia","volume":"94","author":"M C Trappenburg","year":"2009","journal-title":"Haematologica"},{"issue":"05","key":"ref86","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12185-017-2302-5","article-title":"Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms","volume":"106","author":"Y Taniguchi","year":"2017","journal-title":"Int J Hematol"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3892\/ol.2017.6459","article-title":"Clinical significance of circulating microparticles in Ph\u2212 myeloproliferative neoplasms","volume":"14","author":"W Zhang","year":"2017","journal-title":"Oncol Lett"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14735\/amko2019109","article-title":"High level of circulating microparticles in patients with BCR\/ABL negative myeloproliferative neoplasm - a pilot study","volume":"32","author":"M H Aswad","year":"2019","journal-title":"Klin Onkol"},{"issue":"09","key":"ref89","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.3324\/haematol.2016.144279","article-title":"Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia","volume":"101","author":"A Charpentier","year":"2016","journal-title":"Haematologica"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.23590","article-title":"Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia","volume":"89","author":"M Marchetti","year":"2014","journal-title":"Am J Hematol"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"C Th\u00e9ry","year":"2018","journal-title":"J Extracell Vesicles"},{"issue":"02","key":"ref93","doi-asserted-by":"crossref","first-page":"e12404","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"J A Welsh","year":"2024","journal-title":"J Extracell Vesicles"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2799-0557.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:44:47Z","timestamp":1771976687000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2799-0557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":92,"URL":"https:\/\/doi.org\/10.1055\/a-2799-0557","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,12]]},"published":{"date-parts":[[2026,2,12]]}}}